Stockscreener 앱 받기
27.80
0.00%
0.00
시간 외 거래:
27.90
0.10
+0.36%
전일 마감가:
$27.80
열려 있는:
$27.6
하루 거래량:
4.01M
Relative Volume:
0.59
시가총액:
$19.90B
수익:
$13.31M
순이익/손실:
$-1.01B
주가수익비율:
-23.79
EPS:
-1.1685
순현금흐름:
$-766.86M
1주 성능:
-2.63%
1개월 성능:
+1.02%
6개월 성능:
+84.84%
1년 성능:
+154.11%
1일 변동 폭
$27.17
$27.93
1주일 범위
$27.17
$29.23
52주 변동 폭
$8.73
$30.33
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
27.80 | 19.90B | 13.31M | -1.01B | -766.86M | -1.1685 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Roivant Sciences Insider Sold Shares Worth $1,200,573, According to a Recent SEC Filing - marketscreener.com
Insider Sell Alert: Melissa Epperly Sells 41,861 Shares of Roiva - GuruFocus
Roivant Sciences (ROIV) director sells 41,861 common shares - Stock Titan
Roivant secures FDA priority review for dermatomyositis treatment - MSN
Aug Catalysts: Can Roivant Sciences Ltd outperform under higher oil prices2026 PreEarnings & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rockefeller Financial files to sell 200,000 Roivant shares | ROIV SEC FilingForm 144 - Stock Titan
Aug Reactions: Is Roivant Sciences Ltd stock undervalued right nowWeekly Stock Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Bamco Inc. NY Acquires 105,000 Shares in Roivant Sciences Ltd. - National Today
105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY - MarketBeat
Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? - MSN
Roivant Sciences Ltd. $ROIV Shares Purchased by HighVista Strategies LLC - MarketBeat
Roivant Sciences Ltd. $ROIV is Foursixthree Capital LP's 7th Largest Position - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Sold by Prosight Management LP - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Bought by Integral Health Asset Management LLC - MarketBeat
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent LitigationSlideshow (NASDAQ:ROIV) 2026-03-13 - Seeking Alpha
Roivant Sciences stock hits all-time high at 30.31 USD - Investing.com Nigeria
Roivant Sciences Hits New 52-Week High at $30.30, Up 180.72% - Markets Mojo
Roivant Sciences stock hits all-time high at 30.31 USD By Investing.com - Investing.com Canada
Leerink Partners maintains Roivant Sciences (ROIV) outperform recommendation - MSN
Roivant at Leerink Conference: Strategic Transformation Insights - Investing.com Australia
Dimensional Fund Advisors LP Has $140.84 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Reaches New 52-Week HighHere's Why - MarketBeat
(ROIV) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Roivant Sciences stock hits all-time high at 29.23 USD - Investing.com Nigeria
WINTON GROUP Ltd Purchases 335,269 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) Gets a Buy from H.C. Wainwright - The Globe and Mail
Aug Rallies: Can Roivant Sciences Ltd. sustain earnings growthQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Roivant Sciences Hits New 52-Week High at $29.20, Up 170.89% - Markets Mojo
Dow Update: Can Roivant Sciences Ltd outperform under higher oil pricesJuly 2025 Intraday Action & Weekly High Return Forecasts - baoquankhu1.vn
Neo Ivy Capital Management Has $3.59 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Blue Owl Capital Holdings LP Acquires New Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) reports Q3 loss, misses revenue estimates - MSN
Sentiment Review: Is Roivant Sciences Ltd stock undervalued right nowGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
HC Wainwright Expects Stronger Earnings for Roivant Sciences - MarketBeat
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Roivant Sciences Hits New 52-Week High at $29.82, Up 179% - Markets Mojo
Roivant Sciences Hits Day High with Strong 6% Intraday Surge - Markets Mojo
Cowen Maintains Buy on Roivant Sciences Ltd (ROIV) March 2026 - Meyka
Roivant Sciences stock hits all-time high at 29.23 USD By Investing.com - Investing.com Canada
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds By Investing.com - Investing.com South Africa
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength - Yahoo Finance
Key facts: Roivant Sciences secures $2.25B settlement; boosts buyback to $1B; price target raised to $34 - TradingView
Moderna to pay up to $2.25B to settle COVID-19 patents case - BioWorld MedTech
Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - TradingView
TD Cowen reiterates Roivant Sciences stock rating on drug launch timing - Investing.com Australia
TD Cowen reiterates Roivant Sciences stock rating on drug launch timing By Investing.com - Investing.com South Africa
Moderna gains as Arbutus/ Genevant settlement removes major financial risk - Seeking Alpha
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $34.00 at HC Wainwright - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Purchased by TD Asset Management Inc - MarketBeat
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):